this series of FREE webinars, we team up with Macmillan Cancer Support and get to quiz several consultant oncologists to demystify some of the conundrums posed by cancer in primary care.
Live date: 11.03.2020
CPD points: 1Info / BookAdd to basket
Join Dr David Plume and guests as they discuss the many issues, guidelines, studies and effects around prostate cancer.
Prostate cancer is the most common cancer in the UK with around 48,000 men a year diagnosed. It can cause premature death, but actually has quite low mortality rates even with advanced disease, unlike many of the cancers that we see.
It’s no surprise therefore that we see a lot of men who are either concerned about prostate cancer, are being treated or monitored with prostate cancer, or have had prostate cancer in the past and are now dealing with the consequences of treatment, and as we move to stratified follow up, and more low risk prostate cancer patients are followed up in the community rather than secondary care, we will see many more!
Join Cancer Course Director Dr David Plume in the Red Whale studio with co-host Dr Richard Simcock, Consultant Clinical Oncologist from Brighton and one of Macmillan’s Consultant Advisors, and our guest Dr Alison Birtle, Consultant Clinical Oncologist and Honorary Clinical Senior Lecturer from Lancashire Teaching Hospitals NHS Foundation Trust.
What we will cover:
- Significant issues around the diagnosis and management of prostate cancer.
- The NICE Guidelines on prostate cancer.
- The STAMPEDE study and what this might mean for our patients.
- Late and long term effects from prostate cancer treatment.
1 CPD hour
Register now by clicking 'Add to basket' above.
The lung cancer landscape is changing. Screening (or case finding!) and immunotherapies are shifting the tides a little more in favour of patients and there are some important things we need to know in primary care.
Lung cancer historically is something we have seen as a death sentence. We have had a fairly nihilistic view of it and this has been understandable given only 5% are potentially curable at diagnosis. However, screening and novel therapies mean one-year survival is starting to creep up and a small sub-set of patients are living with lung cancer as a long term condition.
This webinar will cover:
- Lung cancer CT case finding (or screening!) is now a reality in many areas of the UK. Do you know how this works and what is means for you and your patients?
- Novel immunotherapies are an option for a small sub-group of patients with non-small cell lung cancer and can radically alter the prognosis. But, they have significant toxicities that can occur many months down the line and present to us in primary care – would you spot them and know what to do?
- How can we best support our patients with lung cancer: we offer some great resources.
Join our cancer course director, GP, David Plume and his guests in the Red Whale studio for the first in the second series of Red Whale cancer webinars in association with Macmillan Cancer Support to discuss this and much more. David will be joined by Dr Richard Simcock, ever-so-practical Consultant Clinical Oncologist from Brighton and Dr Tom Newsom-Davis, who is a Consultant Medical Oncologist at the Chelsea and Westminster specialising in thoracic malignancies and the vice chair of the British Thoracic Oncology Group Steering Committee. Between them, they should be able to answer all your questions!
Add to basket
The fifth commonest cause of cancer death, and the worst one-year survival rate of any cancer. Why?
What we cover:
- Why aren’t we seeing many of these patients earlier?
- What key symptoms should we be watching for?
- What investigations are useful in suspected pancreatic cancer?
- What are the treatment options?
- How do we handle ongoing management of these patients?
Add to basket